Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Lakeland, FL
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Lakeland, FL
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Miami Beach, FL
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Orange Park, FL
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Chicago, IL
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Chicago, IL
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Niles, IL
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Niles, IL
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Detroit, MI
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Detroit, MI
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Hattiesburg, MS
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Lincoln, NE
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Morristown, NJ
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Canton, OH
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Canton, OH
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Columbus, OH
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Columbus, OH
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Middletown, OH
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Middletown, OH
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Portland, OR
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Portland, OR
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Knoxville, TN
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Everett, WA
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Everett, WA
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Caba,
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Caba,
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Washington,
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Washington,
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Dendritic Cell Activating Scaffold in Melanoma
A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Dendritic Cell Activating Scaffold in Melanoma
A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Dendritic Cell Activating Scaffold in Melanoma
A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dendritic Cell Activating Scaffold in Melanoma
A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group SC
mi
from
Fayetteville, AR
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group SC
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists Dept of Oncology (2)
mi
from
Fort Myers, FL
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists Dept of Oncology (2)
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists SC
mi
from
Fort Myers, FL
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists SC
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Oncology Specialists, SC SC - 5
mi
from
Park Ridge, IL
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Oncology Specialists, SC SC - 5
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center for Cancer SC
mi
from
Goshen, IN
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center for Cancer SC
mi
from
Goshen, IN
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Eastern Maine Medical Center Research Center SC
mi
from
Bangor, ME
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Eastern Maine Medical Center Research Center SC
mi
from
Bangor, ME
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Weinberg Cancer Institute at Franklin Square Hospital Dept of Oncology
mi
from
Baltimore, MD
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Weinberg Cancer Institute at Franklin Square Hospital Dept of Oncology
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital SC -6
mi
from
Boston, MA
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital SC -6
mi
from
Boston, MA
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology, P.A. Fridley Location
mi
from
Minneapolis, MN
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology, P.A. Fridley Location
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Nebraska Methodist Hospital Estabrook Cancer Center
mi
from
Omaha, NE
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Nebraska Methodist Hospital Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Cooper Cancer Center SC
mi
from
Camden, NJ
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Cooper Cancer Center SC
mi
from
Camden, NJ
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center SC-2
mi
from
Hackensack, NJ
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center SC-2
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State University
mi
from
Columbus, OH
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Northwest Dept of Kaiser Northwest (3)
mi
from
Portland, OR
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Northwest Dept of Kaiser Northwest (3)
mi
from
Portland, OR
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists Compass Oncology - SC
mi
from
Portland, OR
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists Compass Oncology - SC
mi
from
Portland, OR
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Science University SC-7
mi
from
Portland, OR
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Science University SC-7
mi
from
Portland, OR
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital and Health Network SC
mi
from
Bethlehem, PA
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital and Health Network SC
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Penn State University / Milton S. Hershey Medical Center SC-2
mi
from
Hershey, PA
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Penn State University / Milton S. Hershey Medical Center SC-2
mi
from
Hershey, PA
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute SC - 2
mi
from
Nashville, TN
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute SC - 2
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. SC
mi
from
Austin, TX
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. SC
mi
from
Austin, TX
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Baylor Health Care System/Sammons Cancer Center Oncology
mi
from
Dallas, TX
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Baylor Health Care System/Sammons Cancer Center Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center SC (5)
mi
from
Dallas, TX
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center SC (5)
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute SC - 1
mi
from
Detroit, MI
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute SC - 1
mi
from
Detroit, MI
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital SC
mi
from
Philadelphia, PA
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital SC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rosario,
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rosario,
Click here to add this to my saved trials
Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
A Phase II Study of Sirolimus in Renal Transplant Patients Diagnosed With New or Recurrent Squamous Cell Skin Carcinoma Currently on Calcineurin-based Immunosuppression.
Status: Enrolling
Updated:  12/31/1969
Shands at the University of Florida
mi
from
Gainesville, FL
Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
A Phase II Study of Sirolimus in Renal Transplant Patients Diagnosed With New or Recurrent Squamous Cell Skin Carcinoma Currently on Calcineurin-based Immunosuppression.
Status: Enrolling
Updated: 12/31/1969
Shands at the University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center Onc Dept
mi
from
San Francisco, CA
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center Onc Dept
mi
from
San Francisco, CA
Click here to add this to my saved trials